{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:52:15Z","timestamp":1790790735228,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ejca.2013.12.002","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T03:48:05Z","timestamp":1388720885000},"page":"1004-1012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010"],"prefix":"10.1016","volume":"50","author":[{"given":"Avinash G.","family":"Dinmohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"van Norden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Huijgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan A.","family":"van de Loosdrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Jongen-Lavrencic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.12.002_b0005","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2007-08-078139","article-title":"Myelodysplastic syndromes","volume":"111","author":"Nimer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.12.002_b0010","series-title":"International classification of diseases for oncology","author":"Fritz","year":"2000"},{"key":"10.1016\/j.ejca.2013.12.002_b0015","series-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.ejca.2013.12.002_b0020","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.12.002_b0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.12.002_b0030","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.12.002_b0035","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2013.12.002_b0040","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","article-title":"Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry","volume":"35","author":"Neukirchen","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2013.12.002_b0045","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.12.002_b0050","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.12.002_b0055","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.12.002_b0060","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.12.002_b0065","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.12.002_b0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","volume":"120","author":"Bowen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2013.12.002_b0075","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.leukres.2010.01.018","article-title":"Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines","volume":"34","author":"Santini","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2013.12.002_b0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6004\/jnccn.2011.0005","article-title":"NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes","volume":"9","author":"Greenberg","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2013.12.002_b0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.12.002_b0090","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.12.002_b0095","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.12.002_b0100","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.12.002_b0105","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2012.064014","article-title":"Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study","volume":"98","author":"Maynadie","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2013.12.002_b0110","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2307\/2529873","article-title":"Cancer survival corrected for heterogeneity in patient withdrawal","volume":"38","author":"Hakulinen","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2013.12.002_b0115","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"88","article-title":"Myelodysplastic syndromes\/neoplasms, overview","author":"Brunning","year":"2008"},{"key":"10.1016\/j.ejca.2013.12.002_b0120","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.12.002_b0125","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model","volume":"29","author":"Naqvi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.12.002_b0130","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.12.002_b0135","first-page":"1596","article-title":"Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes","volume":"91","author":"Germing","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2013.12.002_b0140","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.24984","article-title":"Cause of death in patients with lower-risk myelodysplastic syndrome","volume":"116","author":"Dayyani","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.12.002_b0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.seminhematol.2007.10.004","article-title":"Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes","volume":"45","author":"Hellstrom-Lindberg","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejca.2013.12.002_b0150","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/leu.2011.391","article-title":"Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study","volume":"26","author":"Germing","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.12.002_b0155","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/leu.2012.369","article-title":"Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis","volume":"27","author":"Kuendgen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.12.002_b0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2013.12.002_b0165","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.12.002_b0170","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.12.002_b0175","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2013.12.002_b0180","unstructured":"Gavin A, Rous B, Marcos-Gragera R, et al. Towards optimal clinical and epidemiological registration of Haematological Malignancies: guidelines for recording progressions, transformations and multiple diagnoses. Eur J Cancer, submitted for publication."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913010563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913010563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:19:57Z","timestamp":1716383997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913010563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0959804913010563"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.12.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2013.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}